CANAGLIFLOZIN ANHYDROUS
Small molecule targets SLC5A2 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 9 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (7) | US (FDA) | INVOKANA | — | 2015-09-10 – 2024-12-18 | fda.gov ↗ |
| Approved | EU (EMA) | Invokana | — | 2013-11-15 | europa.eu ↗ |
| Approved | US (FDA) | INVOKANA | — | 2013-03-29 | fda.gov ↗ |
Trials 112 · started per year
Also used as a comparator or background therapy in 26 trials
Evidence & citations 22 cited values
Every value below carries the sentence it was read from. 144 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CANAGLIFLOZIN ANHYDROUS | ChEMBL registry synonym — accepted as the source's own label CHEMBL2048484 ↗ |
| Known as | 28431754 | “A Study of 28431754 (Canagliflozin) on Gastrointestinal Glucose Absorption and Metabolism in Healthy Volunteers” NCT01173549 ↗1“A Pharmacokinetic and Bioavailability Study of 28431754 (Canagliflozin) in Healthy Male Volunteers” NCT01157000 ↗ |
| Known as | CANA | “The purpose of this study is to assess the effect of coadministration of a high-fat meal on the oral bioavailability of a fixed dose combination of Canagliflozin/extended...” NCT02039258 ↗3“Canagliflozin (CANA), a kind of sodium-glucose cotransporter-2 (SGLT-2) inhibition, study in which the role of CANA monotherapy in polycystic ovary syndrome (PCOS) has been investigated” PMID 36147577 ↗ Sep 2022 “canagliflozin 100 mg/day (CANA), or 3) liraglutide 1.2 mg plus canagliflozin 100 mg (CANA/LIRA) for 16 weeks.” PMID 32220916 ↗ Mar 2020 “canagliflozin (CANA), a sodium-glucose cotransporter 2 (SGLT2) inhibitor” PMID 26786577 ↗ Jan 2016 |
| Known as | Canagliflozin | “A Single-Dose, Open-Label, Randomized, 2-Period Crossover Study to Assess the Effect of Food Coadministration on the Pharmacokinetics of a Fixed Dose Combination Tablet of...” NCT02039258 ↗130“To assess the effect of food on the pharmacokinetics (PK) of canagliflozin and metformin following administration of a canagliflozin/metformin (150/1,000 mg) immediate-release...” PMID 25546166 ↗ Mar 2015 “Canagliflozin is an orally active, selective, reversible sodium-glucose cotransport-2 (SGLT-2) inhibitor used in patients with chronic kidney disease (CKD) to prevent...” PMID 40952584 ↗ Sep 2025 “This study is designed to mitigate the effects of glucose with intermittent oral Canagliflozin for healthy, non-diabetic volunteers of any sex who enroll in the study.” NCT06301529 ↗ “This review summarizes data on the effect of SGLT2 inhibitors marketed in the US (namely canagliflozin, dapagliflozin, or empagliflozin) on BP in patients with T2DM.” PMID 27822054 ↗ Oct 2016 “Intervention: Dapagliflozine 10 mg once daily tablet treatment or Empagliflozin10 mg once daily tablet treatment or Canagliflozin 100 mg once daily tablet treatment.” NCT04127084 ↗ “Chemical Name: Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors (e.g., Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin) Class: SGLT2 Inhibitors” NCT06449235 ↗ “Each tablet contains Canagliflozin/extended release Metformin (CANA/MET XR) fixed dose combination (FDC) of 150 mg/1,000 mg, to be taken orally (by mouth)” NCT02039245 ↗ “receive combination of metformin, pioglitazone, and an SGLT2 inhibitor (empagliflozin or dapagliflozin or canagliflozin)” NCT04419337 ↗ “Canagliflozin will be started at 100 mg daily per oral administration, and augmented to 300 mg/per day if required” NCT04196231 ↗ “SGLT2 inhibitors (dapagliflozin, empagliflozin, canagliflozin) - recommended for people with T2D + CKD” NCT07391267 ↗ “A 600 mg dose of canagliflozin (two 300 mg tablets) will be administered orally by the participant” NCT07527390 ↗ “All participants will be receive 100 mg/daily doses of Canagliflozin (INVOKANA) for 6 months.” NCT06291155 ↗ “SGLT2 inhibitors: Empagliflozin up to 25mg daily, Canagliflozin up to 300mg daily” NCT02041234 ↗ “treated with either metformin (n = 35) or canagliflozin (n = 33) for 12 weeks.” PMID 41401816 ↗ Dec 2025 “dapagliflozin","empagliflozin","canagliflozin","ertugliflozin” NCT04505774 ↗ “Canagliflozin,100mg once daily, orally, for 6 months” NCT07711171 ↗ “Empagliflozin, dapagliflozin, or canagliflozin” NCT05390892 ↗ “Canagliflozin (SGLT-II inhibitor, 100 mg)” NCT04027023 ↗ “canagliflozin (100mg daily)” NCT02528019 ↗ “canagliflozin (Invokana®)” NCT07325435 ↗ “Canagliflozin” NCT02041234 ↗ “canagliflozin” NCT04662723 ↗ |
| Known as | canagliflozin (Invokana) | “canagliflozin (Invokana®)” NCT07325435 ↗ |
| Known as | Canagliflozin component of invokamet | ChEMBL registry synonym — accepted as the source's own label CHEMBL2048484 ↗ |
| Known as | Canagliflozin hemihydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2048484 ↗ |
| Known as | Canagliflozin hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2048484 ↗ |
| Known as | Canagliflozina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2048484 ↗ |
| Known as | Canagliflozine | ChEMBL registry synonym — accepted as the source's own label CHEMBL2048484 ↗ |
| Known as | Invokana | “A Phase 1, Single-center, Partially Double-blind, Randomized, Single-dose, 3-Period Crossover Study to Assess the Pharmacodynamic Effects of LX4211 and INVOKANA™...” NCT01916863 ↗3“Invokana (Canagliflozin) might act as a potent dual inhibitor of AChE and SGLT2.” NCT04304261 ↗ “Canagliflozin (Invokana) 300 mg tablet” NCT06182839 ↗ |
| Known as | Invokana (brand name for canagliflozin) | “Invokana (brand name for canagliflozin)” NCT02891954 ↗ |
| Known as | InvokanaTM | “Canagliflozin (sold as InvokanaTM) is a new medicine for diabetes.” NCT02404870 ↗ |
| Known as | JNJ-24831754 | “A Study of the Effects of Canagliflozin [JNJ-24831754] on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus (CANVAS-R)” PMID 36302584 ↗ Nov 2022 |
| Known as | JNJ-24831754-ZAE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2048484 ↗ |
| Known as | JNJ-28431754 | “The purpose of this study is to investigate the absorption (the way the drug enters the body), metabolism (the way the drug is broken down in the body), and excretion (the way...” NCT01791231 ↗21“An Open-Label, Single-Dose Study to Assess the Absolute Oral Bioavailability and Pharmacokinetics of JNJ-28431754 (Canagliflozin) Administered as a 300-mg Oral Tablet and an...” NCT01157000 ↗ “An Open-Label Drug Interaction Study to Assess the Pharmacokinetics and Pharmacodynamics of Warfarin When Administered Alone and in Combination With Multiple-Dose JNJ-28431754...” NCT01195324 ↗ “A Double-Blind, Randomized, Placebo Controlled, 2-Period Crossover Study to Evaluate the Effect of a Single Dose of JNJ-28431754 (Canagliflozin) on Gastrointestinal Glucose...” NCT01173549 ↗ “A Double-Blind, Placebo-Controlled, Randomized, Parallel-Groups Study to Investigate the Effects of JNJ-28431754 (Canagliflozin) on Plasma Volume and Renal Function in Subjects...” NCT01483781 ↗ “This is an open-label (volunteers and study staff will know the name and dose of the treatment assigned), single-center study of canagliflozin (JNJ-28431754) in healthy adult...” NCT01281579 ↗ “The purpose of this study is to assess the effect of canagliflozin (JNJ-28431754) compared to placebo in the treatment of participants with Type 2 Diabetes Mellitus (T2DM)” NCT02025907 ↗ “This is an open-label (volunteers will know the names of treatments they are assigned), single-center study of canagliflozin (JNJ-28431754) in healthy adult volunteers.” NCT01286103 ↗ “Canagliflozin (also referred to as JNJ-28431754) is a drug that is being tested to see if it may be useful in treating patients diagnosed with T2DM.” NCT01064414 ↗ “Canagliflozin (JNJ-28431754) will be given orally as over-encapsulated tablets, at a dose of 100 mg or 300 mg once daily for 104 weeks.” NCT00968812 ↗ “The purpose of this study is to evaluate the effect of canagliflozin (JNJ-28431754) on blood pressure reduction, compared to placebo” NCT01939496 ↗ “A Study to Evaluate the Effect of JNJ-28431754 (Canagliflozin) on Post-Meal Glucose in Patients With Type 2 Diabetes Mellitus” NCT01381887 ↗ “A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus” NCT01989754 ↗ “One 300 mg dose of canagliflozin (JNJ-28431754)” NCT01787357 ↗ “Drug: Canagliflozin (JNJ-28431754) 100 mg” NCT01032629 ↗ “300 mg JNJ-28431754 (Canagliflozin)” NCT01186588 ↗ “Canagliflozin (JNJ-28431754)” NCT01756417 ↗ “Canagliflozin (JNJ-28431754)” NCT02009488 ↗ “Canagliflozin (JNJ-28431754)” NCT00650806 ↗ “JNJ-28431754 (Canagliflozin)” NCT01128985 ↗ |
| Known as | JNJ-28431754-AAA | ChEMBL registry synonym — accepted as the source's own label CHEMBL2048484 ↗ |
| Known as | TA-7284 | “Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus” NCT02220920 ↗ |
| Action | Inhibit | “canagliflozin, a sodium glucose co-transporter 2 inhibitor” PMID 22632452 ↗ Jun 20121“Sodium/glucose cotransporter 2 inhibitor” CHEMBL2048484 ↗ |
| Modality | Small molecule | — CHEMBL2048484 ↗ |
| Route | Oral | “One 50 mg, 100 mg, 200 mg, or 300 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks or one 300 mg over-encapsulated tablet orally twice daily for 12 weeks” NCT00642278 ↗ |
| Target | SLC5A2 | “Sodium/glucose cotransporter 2 inhibitor” CHEMBL2048484 ↗ |